Chinese University of Hong Kong, Hong Kong, China; School of Biomedical Sciences, Faculty of Medicine, Hong Kong, China; Shenzhen Research Institute, Chinese University of Hong Kong, Shenzhen, China.
School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China.
Biomed Pharmacother. 2022 Jul;151:113172. doi: 10.1016/j.biopha.2022.113172. Epub 2022 May 26.
Diabetic vasculopathy is a major health problem worldwide. Peripheral arterial disease (PAD), and in its severe form, critical limb ischemia is a major form of diabetic vasculopathy with limited treatment options. Existing literature suggested an important role of PPARδ in vascular homeostasis. It remains elusive for using PPARδ as a potential therapeutic target due to mostly the side effects of PPARδ agonists. To explore the roles of PPARδ in endothelial homeostasis, endothelial cell (EC) selective Ppard knockout and controlled mice were subjected to hindlimb ischemia (HLI) injury. The muscle ECs were sorted for single-cell RNA sequencing (scRNA-seq) analysis. HLI was also performed in high fat diet (HFD)-induced obese mice to examine the function of PPARδ in obese mice with delayed vascular repair. Adeno-associated virus type 1 (AAV1) carrying ICAM2 promoter to target endothelium for overexpressing PPARδ was injected into the injured muscles of normal chow- and HFD-fed obese mice before HLI surgery was performed. scRNA-seq analysis of ECs in ischemic muscles revealed a pivotal role of PPARδ in endothelial homeostasis. PPARδ expression was diminished both after HLI injury, and also in obese mice, which showed further delayed vascular repair. Endothelium-targeted delivery of PPARδ by AAV1 improved perfusion recovery, increased capillary density, restored endothelial integrity, suppressed vascular inflammation, and promoted muscle regeneration in ischemic hindlimbs of both lean and obese mice. Our study indicated the effectiveness of endothelium-targeted PPARδ overexpression for restoring functional vasculature after ischemic injury, which might be a promising option of gene therapy to treat PAD and CLI.
糖尿病血管病变是全球范围内的一个主要健康问题。外周动脉疾病(PAD),及其严重形式——肢体严重缺血,是糖尿病血管病变的主要形式,其治疗选择有限。现有文献表明,过氧化物酶体增殖物激活受体 δ(PPARδ)在血管稳态中起着重要作用。由于 PPARδ 激动剂的副作用,将其作为一种潜在的治疗靶点仍然难以实现。为了探索 PPARδ 在血管内皮稳态中的作用,我们对内皮细胞(EC)选择性敲除 Ppard 的小鼠和对照小鼠进行了后肢缺血(HLI)损伤实验。对肌肉 EC 进行了单细胞 RNA 测序(scRNA-seq)分析。还在高脂饮食(HFD)诱导肥胖小鼠中进行了 HLI,以研究 PPARδ 在肥胖小鼠血管修复延迟中的作用。携带细胞间黏附分子 2(ICAM2)启动子的腺相关病毒 1(AAV1)用于靶向内皮细胞过表达 PPARδ,在进行 HLI 手术前,将其注射到正常饲料和 HFD 喂养的肥胖小鼠的损伤肌肉中。对缺血肌肉中的 ECs 进行 scRNA-seq 分析,揭示了 PPARδ 在血管内皮稳态中的关键作用。在 HLI 损伤后和肥胖小鼠中,PPARδ 的表达均减少,这表明血管修复进一步延迟。通过 AAV1 靶向内皮细胞的 PPARδ 过表达,改善了灌注恢复,增加了毛细血管密度,恢复了内皮完整性,抑制了血管炎症,并促进了缺血后肢的肌肉再生。我们的研究表明,在缺血性损伤后,通过靶向内皮细胞过表达 PPARδ 来恢复功能性血管是有效的,这可能是治疗 PAD 和 CLI 的基因治疗的一种有前途的选择。